Novo Nordisk, Wegovy
Novo Nordisk Shares Drop More Than 4% on Disappointing Obesity Pill Data
Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of monlunabant, an experimental drug it acquired as part of its $1 billion purchase of Canadian biotech company Inversago Pharmaceuticals last year.
Shares in Novo Nordisk (NYSE: NVO) fell more than 4% following the market open on Friday after the Danish pharma giant released data from a phase 2a clinical trial with its obesity drug, monlunabant.
Based on the results of the trial, drugmaker Novo Nordisk has asked U.S. regulators to expand use of the medication for ...
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...
1d
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo ...
GlobalData on MSN19h
Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseasesNanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback